News headlines about Raptor Pharmaceutical Corp (NASDAQ:RPTP) have been trending somewhat positive on Thursday, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Raptor Pharmaceutical Corp earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.649780273536 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Raptor Pharmaceutical Corp (NASDAQ RPTP) opened at 9.00 on Thursday. The company has a 50-day moving average price of $8.81 and a 200 day moving average price of $6.51. Raptor Pharmaceutical Corp has a 12-month low of $2.94 and a 12-month high of $9.05.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Raptor Pharmaceutical Corp (RPTP) Stock Price” was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at

Raptor Pharmaceutical Corp Company Profile

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Insider Buying and Selling by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)

Receive News & Ratings for Raptor Pharmaceutical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp and related companies with's FREE daily email newsletter.